Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering
Biotech Finally Has an IPO After Months-Long Freeze
Details : The biotech will use the proceeds from the raise to support the entry of lead asset LB-102, a potent antagonist of dopamine D2/3 and 5HT7 receptors, into Phase III testing for schizophrenia.
Product Name : LB-102
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 25, 2025
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LB-102 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
Details : LB-102 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
Details : LB-102 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 05, 2019
Lead Product(s) : Lb-102
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable